Kornimate/medical-research-clean huggingface dataset:
this scr-103 protocol will permit sites to proactively assess taa, hla and hpv-16 status in patients with selected solid tumors to determine suitability for repertoire immune medicines treatment protocols.

Conditions: Head and Neck Cancer; Melanoma; HPV-Related Malignancy; HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Lung Cancer, Nonsmall Cell; Melanoma (Skin)

Summary: the purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with head and neck, cervical, melanoma and non-small cell lung cancers to assess antigen expression and patient suitability for a repertoire immune medicines treatment protocol.

this screening study is intended for men and women at least 18 years of age who have selected advanced solid tumors. the study will assess the patient's selected tumor antigens and/or hpv-16 e6/e7 expression profiles. human leukocyte antigen (hla) subtype will also be assessed. based on the results, it will be determined if a patient is eligible to be considered for a repertoire immune medicines sponsored clinical trial(s) testing of the safety and efficacy of a multi-antigen cytokine-enhanced t cell therapy. no treatment intervention will occur as part of this screening study. upon enrollment, patients will be required to provide archival tumor tissue and saliva samples. based upon the results of these diagnostic analyses, if eligible, patients may be enrolled in an appropriate interventional clinical trial(s) at the discretion of the investigator.

Eligibility criteria:
inclusion criteria: * be willing and able to provide written informed consent * age ≥ 18 years * histologically- or cytologically-confirmed, relapsed/refractory, and metastatic or locally advanced head and neck, cervical, melanoma or non-small cell lung cancers. other solid tumor types may be analyzed at the discretion of the sponsor * able to provide archived tumor tissue or have existing data on taas, hpv status or hla sub-type * willing to provide a saliva sample exclusion criteria: * there are no exclusion criteria for this study.

Keywords: hpv-16 e6/e7 tt-101 prime-102 metastatic solid tumor
management of palmar hyperhidrosis with hydrogel-based iontophoresis

Conditions: Hyperhidrosis; Hyperhidrosis Palmaris et Plantaris

Summary: this study will evaluate the use of hydrogel electrode pads (rather than tap water baths) to deliver iontophoresis treatment using a traditional iontophoresis device. participants will treat one hand with the hydrogel-based iontophoresis device and leave the other hand untreated.

palmar hyperhidrosis affects 4.3 million americans and results in substantial quality of life impairment. treatment options for palmar hyperhidrosis include antiperspirants, systemic anticholinergic agents, botulinum toxin injections, and iontophoresis. standard iontophoresis involves submerging the hands in tap water through which current is applied to the palms for 30 minutes per day up to 3 times per week. while effective, treatment adherence rates are low. this study will evaluate the use of hydrogel electrode pads (rather than tap water baths) to deliver iontophoresis treatment using a traditional iontophoresis device. hydrogel electrode pads permit improved mobility and hand functionality during iontophoresis treatment sessions.

Eligibility criteria:
inclusion criteria: * 13 years of age or older * \>6 months self-reported history of primary palmar hyperhidrosis * initial gravimetry test: \>20mg/min on each palm * no topical treatments for hyperhidrosis (antiperspirants) on the palms for 2 weeks prior to the start of the study * no systemic treatments for hyperhidrosis (anticholinergics) for 4 weeks prior to the start of the study * no tap water iontophoresis treatment for 6 weeks * no botox injections on the palms for 6 months (if single treatment session) or 10 months (if \>1 previous sessions) prior to the start of the study * no history of cardiothoracic sympathectomy for hyperhidrosis * able to attend 3 office visits (stanford medical outpatient center located at 450 broadway st, redwood city, ca 94063; lucile packard children's hospital at 730 welch road, 1st floor, palo alto, ca 94304) and one virtual visit in an 8 week time frame * capable of performing sweat level testing and hydrogel-based iontophoresis treatment at home, after training * hydrogel electrode pad fits on the hand (typically tip of middle finger to lower end of palm length of 6.5in (16.5cm) or greater) exclusion criteria: * patients with implanted electronic medical devices e.g. pacemaker, implantable cardioverter/defibrillator) * patients with metal implants in the extremity that will be treated * patients with larger skin defects (on the palm or arm of the extremity that will be treated) that cannot be covered by petroleum jelly * pregnant or nursing women, or looking to become pregnant * patients on medications that interfere with neuroglandular transmission * patients with active infection locally or systemically * patients with history of contact dermatitis to acrylates * patients with history of contact or systemic allergy to iodine * patients with a history of ischemic heart disease, cardiac arrhythmias, epilepsy or thyroid disease

Keywords: hyperhidrosis palmar sweating iontophoresis sweat gland diseases skin diseases
exercise training to lose weight in obese asthmatics

Conditions: Asthma; Obesity

Summary: obese asthmatics have more severe symptoms, reduced lung function, poorer quality of life and a reduced response to inhaled corticosteroid medication compared to non-obese asthmatics. in addition, the impact of a weight-loss program on clinical control and psychological outcomes has been poorly demonstrated and the effect of exercise training remain unknown. the investigators aim to investigate the effect of exercise training in a weight-loss program on asthma clinical control (primary outcome), health factors related to quality of life and psychosocial symptoms (secondary outcomes) in obese patients with moderate-to-severe persistent asthma. physical activity, inflammatory profiles and sleep disorders will also be evaluated. the investigators' hypothesis is that exercise as part of a weight-loss program is more effective to lose weight and improve asthma control, quality of life and psychosocial symptoms in obese asthmatics.

this is a randomized, controlled and single blinded trial. fifty-four asthmatic adults will be randomly assigned into two groups: dbg (dietary and behavioral support group) or dbe (similar to dbg + exercise training). both groups will complete a weight-loss program based on dietary and behavioral therapy. in addition, dbe will perform a training program based on aerobic and resistance training whereas dbg will perform a breathing and stretching program. interventions will be performed twice a week for 3 months, 60 minutes each. the data normality will be analyzed by kolmogorov-smirnov, the variables obtained before interventions will be compared with the student t-test or mann-whitney u-test. comparisons of the initial and final data on outcomes will be analyzed with repeated measures anova with appropriate post hoc of bonferroni. the significance level will be set to 5% for all tests.

Eligibility criteria:
inclusion criteria: * asthma moderate and severe * asthma will diagnosed (global initiative for asthma -gina) * body mass index between 35 kg/ m2 and 39,9 kg/m2 * sedentary * medical treatment, for at least 6 months * clinically stable (i.e., no exacerbation or medication changes for at least 30 days) exclusion criteria: * cardiovascular, musculoskeletal or other chronic lung diseases * active cancer * pregnant * weight loss more than 5 % in the preceding 6 months * using weight-loss medications * history of bariatric surgery, uncontrolled hypertension or diabetes * using overnight continuous positive airway pressure * lactating * current or ex-smoker

Keywords: asthma obesity clinical control exercise weight-loss
a phase 1, safety, tolerability and pharmacokinetic profile of intravitreous injections of e10030 (anti-pdgf pegylated aptamer) in subjects with neovascular age-related macular degeneration

Conditions: Age-related Macular Degeneration

Summary: the objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of e10030 intravitreous injection when administered as monotherapy or in combination with lucentis® 0.5 mg/eye in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (amd).


Eligibility criteria:
inclusion criteria: subfoveal choroidal neovascularization (cnv) due to amd exclusion criteria: * any of the following underlying diseases including: * diabetic retinopathy. * history or evidence of severe cardiac disease (e.g., nyha functional class iii or iv - see appendix 19.6), history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months, ventricular tachyarrythmias requiring ongoing treatment. * history or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation. * clinically significant impaired renal (serum creatinine \>2.5 mg/dl or s/p renal transplant or receiving dialysis) or hepatic function. * stroke (within 12 months of trial entry). * any major surgical procedure within one month of trial entry. previous therapeutic radiation in the region of the study eye. any treatment with an investigational agent in the past 60 days for any condition. known serious allergies to the fluorescein dye used in angiography, to the components of the ranibizumab formulation, or to the components of the e10030 formulation.
a study of roactemra/actemra (tocilizumab) in combination with methotrexate in patients with severe active rheumatoid arthritis, comparing tapering versus maintaining the methotrexate dosage

Conditions: Rheumatoid Arthritis

Summary: this randomized, placebo-controlled, double-blind study will compare the safety and efficacy of tapering methotrexate (mtx) versus maintaining mtx dosage in patients with severe active rheumatoid arthritis and an inadequate response to disease-modifying antirheumatic drugs (dmards) initiated on treatment with tocilizumab. participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks and mtx orally weekly throughout the study. at week 24, participants achieving a good/moderate eular response will be randomized receiving the mtx tapering arm or mtx maintenance arm. up to week 56 participants will receive either tapering or stable dose mtx in combination with tocilizumab. from week 56 to week 72 participants will receive tocilizumab monotherapy.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * active severe rheumatoid arthritis (das28 \> 5.1) according to european league of rheumatism (eular)/american college of rheumatology (acr) criteria * inadequate response to a trial of 2 dmards, including methotrexate, a trial being defined as 6 months with 2 months at standard dose; no previous treatment with a biologic agent such as a tumor necrosis factor (tnf) inhibitor * oral corticosteroids must have been at a stable dose of \</= 10 mg/day prednisolone or equivalent for at least 25 out of 28 days prior to start of treatment (day 1) exclusion criteria: * major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization * rheumatic autoimmune disease other than rheumatoid arthritis * functional class iv as defined by the acr classification of functional status in ra * prior history of or current inflammatory joint disease other than ra * previous treatment with tocilizumab * previous treatment with any biologic drug (e.g. tnf inhibitor) that is used in the treatment of ra * intraarticular or parenteral corticosteroids within 6 weeks prior to enrollment * inadequate liver, bone marrow or hepatic function * positive for hepatitis b, hepatitis c or hiv infection * pregnant or breastfeeding women * females of child-bearing potential who are not using reliable means of contraception * history of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies * active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections * history of, or currently active, primary or secondary immunodeficiency
remineralization effects of hydroxyapatite toothpaste

Conditions: Caries, Dental

Summary: the objective of this in situ clinical study is to determine whether a toothpaste containing hydroxyapatite microclusters is as effective as a fluoridated kid's toothpaste in promoting remineralization of early caries lesions and inhibiting the development of caries lesions.

the investigators hypothesize that (1) both the hydroxyapatite and the fluoridated toothpaste promote caries remineralization that is significantly greater than zero, and (2) the two toothpaste formulations are equally effective with respect to post-treatment remineralization and inhibition of demineralization. * non-inferiority will be considered established if there is no statistically significant difference in percentage of remineralization between the hydroxyapatite-containing toothpaste and the fluoridated kid's toothpaste for any one measurement method. * superiority/inferiority will be considered established if at least 20% statistically significant difference is observed between the hydroxyapatite-containing toothpaste and the fluoridated kid's toothpaste for any one measurement method

Eligibility criteria:
inclusion criteria: 1. male and/or female subjects 18 to 50 years inclusive 2. minimum of 20 natural uncrowned teeth (excluding third molars) must be present 3. willing to wear retainer 24 hours per day 4. no active, unrestored cavities 5. have normal salivary flow rate (stimulated and unstimulated flow of ≥0.7 ml/min and ≥0.2 ml/min respectively) ascertained from a preliminary sialometry test 6. available throughout entire study 7. willing to use only assigned products for oral hygiene throughout the duration of the study 8. must give written informed consent 9. must be in good general health 10. no known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study exclusion criteria: 1. advanced periodontal disease 2. medical condition which requires premedication prior to dental visits/procedures 3. not enough teeth to secure the oral retainer 4. diseases of the soft or hard oral tissues 5. wearing of an orthodontic retainer(s) 6. impaired salivary function 7. current use of drugs that can affect salivary flow 8. use of antibiotics one (1) month prior to or during this study 9. positive urine test for pregnancy or self-reported breastfeeding. a urine pregnancy test will be performed on female subjects of child-bearing potential. 10. participation in another clinical study one (1) week prior to the start of the washout period or during this study period 11. use of tobacco products 12. allergic history to common toothpaste ingredients 13. allergic history to amino acids 14. immune compromised individuals (hiv, aids, immuno-suppressive drug therapy) as determined by review of medical history
pioglitazone treatment in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: in this study, the investigators wish to investigate how pioglitazone treatment effects hirsute women. hirsute women are often overweight and have an increased amount of male sex hormone in their blood. their blood tests show frequent changes corresponding to the changes seen in diabetic patients. pioglitazone is a drug used for increasing the insulin sensitivity in diabetic patients. previous studies showed that this drug is able to decrease the level of insulin in blood in hirsute women. moreover, the level of male sex hormones is reduced during this treatment. the drug has only been marketed for few years, and no investigations have been carried out as to the reaction of other hormones, e.g. growth hormone and stress hormone, using this treatment. this clinical trial includes 30 strongly hirsute women. the patients are randomized to either placebo or an active drug. the treatment period is 16 weeks. the patients included must be healthy and take no medicine possibly changing the results of the study. the patients must take no contraceptive pills or receive any other hormone treatment. in connection with the investigation, the following will be carried out on all patients: glucose tolerance test, clinical examination, blood tests, measurement of stress hormones and sex hormones, hyperinsulinaemic euglycaemic clamp test, muscle biopsies and bone scan. this examination programme will be carried out before start of pioglitazone or placebo treatment and again after 16 weeks of treatment. the examinations require 2½ days of hospitalization. the purpose of the study is to gain more knowledge of the reasons for hirsute women to grow more hair than normal women. the study will show whether pioglitazone treatment can reduce the amount of male sex hormone in blood and how the level of stress hormone and growth hormone is changed when reducing the amount of insulin in blood.


Eligibility criteria:
inclusion criteria: * irregular menses, i.e. cyclus length of \>36 days * premenopausal * increased fasting insulin \> 50 pmol/l * increased free testosterone \> 0.035 nmol/l exclusion criteria: * age: \<18 years * contraceptive pill within the past 3 months * postmenopausal (increased fsh) * known diabetes mellitus, endocrine disease or other disease requiring treatment * drug use * pregnancy * planned pregnancy during the treatment period * increased liver parameters

Keywords: polycystic ovary syndrome (pcos) ppargamma growth hormone insulin resistance pioglitazone glucose metabolism microarray
evaluate the safety and efficacy of adgre2 car-t in patients with r/r aml

Conditions: AML

Summary: this is an open label, phase i study to assess the safety and efficacy of adgre2 car-t in patients with relapsed and refractory acute myeloid leukemia


Eligibility criteria:
inclusion criteria: 1. all subjects must sign and date the informed consent before initiating any study specific procedures or activities; 2. diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (aml); 3. the expression of adgre2 in aml blast is positive ; 4. the patient has recovered from the toxicity of previous treatment; 5. ecog score ≤ 2 and expected survival period is not less than 3 months; 6. adequate organ function defined as: ast ≤3×uln; alt ≤3×uln; total bilirubin ≤1.5×uln; serum creatinine ≤1.5×uln, or ccr≥60 ml/min; hemoglobin ≥60g/l ; indoor oxygen saturation ≥92%; lvef≥45%; 7. pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test; 8. from the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception exclusion criteria: 1. diagnosis of acute promyelocytic leukemia; 2. history or presence of a cns disorder; 3. hbsag or hbcab are positive; hcv 、hiv and syphilis antibody are positive, cmv dna in peripheral blood is more than≥500 copies /ml; 4. history of severe hypersensitivity reaction; 5. history of myocardial infarction, cardiac angioplasty or stenting, unstable angina, new york heart association class ii or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment; 6. history of organ transplant surgery; 7. required systemic application of immunosuppressive or other drugs; 8. auto-sct within the 3 months before enrollment; 9. active autoimmune or inflammatory diseases of the nervous system (e.g., guillain-barre syndrome (gbs), amyotrophic lateral sclerosis (als)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (pres)); 10. requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (tls)) ; 11. presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management; 12. live vaccine received within the ≤ 4 weeks before enrollment; 13. persons with serious mental illness; 14. history of major surgical operations four weeks before enrollment; 15. history of alcoholism or substance abuse; 16. was identified by the investigators as unsuitable to participate in the study
the effect of viral load on intrahepatic recurrence in hepatitis b virus (hbv)-related hepatocellular carcinoma (hcc)

Conditions: Carcinoma, Hepatocellular; Chronic Hepatitis B

Summary: the purpose of this study is to evaluate the effect of serum hepatitis b virus (hbv) dna level on intrahepatic recurrence in locally treatable hepatocellular carcinomas (hccs) related with hbv.

prospective cohort study survival * overall survival rate * disease free survival rate recurrence * cumulative recurrence rate

Eligibility criteria:
inclusion criteria: * child-pugh class a or b * maximal tumor size less than 5 cm * no previous history of treatment for hepatocellular carcinoma * recurrent hepatocellular carcinoma located more than 2 cm from the previous cancer site and is found more than 1 year's gap exclusion criteria: * hepatocellular carcinoma in portal vein * hepatocellular carcinoma in hepatic vein

Keywords: hbv dna hcc recurrence peit rfta
the value of high-resolution ultrasound in the detection of lymph node metastasis: a proposal of ni-rads

Conditions: Breast Neoplasms

Summary: the status of axillary lymph node (aln) is an important reference indicator for breast cancer surgery and systemic treatment, which is also an important prognostic indicator for breast cancer. therefore, it is extremely important for surgeons to accurately determine whether axillary lymph nodes have metastasis and the number of metastatic lymph nodes. the value of ultrasound diagnosing the status of axillary lymph nodes was controversial in recent publications. therefore, there is a high need to prove the accuracy and precision of ultrasound for axillary lymph node metastasis in breast cancer patients. the aim of this study is to assess the usefulness of ultrasound in the diagnosis of axillary lymph node status in breast cancer patients by gathering in vivo and vitro ultrasonographic parameters to build a clinical useful categorization system

to facilitate the non-invasive assessment of lymph node status preoperatively, we use ultrasound to detect lymph node metastasis. we designed this study to obtain in vivo and vitro ultrasound features and parameters. before surgery, the detailed ultrasound features are collected during routine ultrasound examination. after the completion of the axillary surgery, fresh lymph node specimens are collected for in vitro ultrasound evaluation one by one in a specially-designed detection system. statistical models are built to categorize the probability of metastasis of lymph node according to a proposed categorization system similar as bi-rads(breast imaging reporting and data system), which is named ni-rads (node imaging reporting and data system).

Eligibility criteria:
inclusion criteria: * histologically confirmed invasive breast cancer. * pathological axillary lymph node staging planned. * axillary lymph node not removed prior to the study. exclusion criteria: * refusal participation in the study.

Keywords: breast neoplasms ultrasonography, interventional biopsy, large-core needle biopsy, fine-needle